# Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC

Source: https://onco.cc/trials/nct07011823/  
OnCo record `nct07011823` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Gangnam Severance Hospital, not yet recruiting.

## Summary

Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC is a phase 2, interventional study registered as NCT07011823 by Gangnam Severance Hospital, with a registry enrolment figure of 20 participants, started 2025-07-16 and due to reach its primary completion in 2027-07-31. Interventions recorded: Partial breast-irradiation. Conditions listed: Triple-Negative Breast Neoplasm. Triple-negative eligibility wording from the registry: "* Patients with triple-negative breast cancer confirmed on tissue biopsy". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: KEY-MELT
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07011823
- Phase: 2
- Setting: Phase II Trial of Immunochemotherapy and Partial Breast Irradiation in Early TNBC With Immune-cold Tumor Environment (KEY-MELT)
- Sponsor: Gangnam Severance Hospital
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07011823: https://clinicaltrials.gov/study/NCT07011823

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07011823.json